PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cells
{{output}}
In the previous studies, it was shown that osimertinib plus durvalumab did not achieve satisfactory efficacy, even inferior to osimertinib alone. We found that PD-L1 blockade impaired the efficacy of osimertinib in EGFR-mutant NSCLC cells despite the presence ... ...
